Organization
Galera Therapeutics
5 clinical trials
1 abstract
Clinical trial
An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2020-08-21
Clinical trial
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic CancerStatus: Terminated, Estimated PCD: 2023-11-30
Clinical trial
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)Status: Terminated, Estimated PCD: 2023-11-28
Clinical trial
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung CancerStatus: Terminated, Estimated PCD: 2021-12-28
Clinical trial
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck CancerStatus: Completed, Estimated PCD: 2021-08-13
Abstract
One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.Org: The University of Iowa Hospitals & Clinics, Nationwide Children’s Hospital, The Ohio State University - James Cancer Hospital, Galera Therapeutics,